In clinical practice, human epididymis protein 4 (HE4) has been utilized as a biomarker of endometrial carcinoma (EC). However, there is a paucity of systematic research on the crucial HE4 levels for detecting various clinical phases and pathological kinds of EC. The accuracy of human epididymis protein 4 (HE4) in the diagnosis of EC was investigated in this study.
Patients who were admitted to Xinjiang Uyghur Autonomous Region People’s Hospital between 2014 and 2019 with a primary complaint of abnormal vaginal bleeding were included in the study. Pathological biopsies confirmed the diagnosis of EC in 136 of the 136 EC patients and 127 of the 127 non-EC patients. SPSS software was used to test the accuracy of HE4 in the diagnosis of EC. The precision of HE4 in detecting various clinical phases and pathological kinds of EC was also investigated.
For endometrial cancer, the critical value of HE4 was 52.40 mmol/L, with a sensitivity of 57.35% and a specificity of 76.38%. The critical value for distinct phases of EC was 36.9 mmol/L, and the sensitivity and specificity were 28 and 87.39%, respectively. The critical value for various pathological kinds was 30.60 mmol/L, with sensitivity and specificity of 93.85% and 33.33%, respectively. HE4 has a moderate diagnostic value for EC, and blood HE4 levels cannot reflect the stage or type of EC.